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Rationale: The effectiveness and safety of aztreonam lysine for in-
halation (AZLI) in patients with cystic fibrosis (CF) on maintenance
treatment for Pseudomonas aeruginosa (PA) airway infection was eval-
uated in this randomized, double-blind, placebo-controlled study.
Objectives: To evaluate the safety and efficacy of inhaled aztreonam
lysine in controlling PA infection in patients with CF.
Methods: After randomization and a 28-day course of tobramycin
inhalation solution (TIS), patients (n 5 211; >6 yr; >3 TIS courses within
previous year; FEV1 > 25% and <75% predicted values) were treated
with 75 mg AZLI or placebo, twice or three times daily for 28 days, then
monitored for 56 days. The primary efficacy endpoint was time to need
for additional inhaled or intravenous antipseudomonal antibiotics.
Secondary endpoints included changes in respiratory symptoms (CF
Questionnaire-Revised [CFQ-R] Respiratory Scale), pulmonary function
(FEV1), and sputum PA density. Adverse events and minimum inhibitory
concentrations of aztreonam for PA were monitored.
Measurements and Main Results: AZLI treatment increased median
time to need for additional antipseudomonal antibiotics for symp-
toms of pulmonary exacerbation by 21 days, compared with placebo
(AZLI, 92 d; placebo, 71 d; P 5 0.007). AZLI improved mean CFQ-R
respiratory scores (5.01 points, P 5 0.02), FEV1 (6.3%, P 5 0.001), and
sputum PA density (20.66 log10 cfu/g, P 5 0.006) compared with
placebo; no AZLI dose–response was observed. Adverse events
reported for AZLI and placebo were comparable and consistent with
CF lungdisease. Susceptibility ofPAtoaztreonamatbaselineandend
of therapy were similar.
Conclusions: AZLI was effective in patients with CF using frequent TIS
therapy. AZLI delayed time to need for inhaled or intravenous
antipseudomonal antibiotics, improved respiratory symptoms and
pulmonary function, and was well tolerated.
Clinical trial registered with www.clinicaltrials.gov (NCT 00104520).
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Cystic fibrosis (CF) is an autosomal recessive disease charac-
terized by pancreatic insufficiency and thick tenacious pulmo-
nary secretions, which often lead to airway infection (1). Among
older patients, the most common pathogen in CF airway
infections is Pseudomonas aeruginosa (PA); these infections
are associated with an accelerated decline in pulmonary func-
tion and increased mortality (2–4).
Over the past 15 years, management of patients with CF has
improved (1, 2, 5–8). However, antimicrobial treatment options for
chronic PA airway infections remain limited and additional ther-
apies are needed to augment improvements in clinical outcomes.
Aztreonam lysine for inhalation (AZLI) is an aerosolized
formulation of the monobactam antibiotic aztreonam and lysine
(9). The intravenous aztreonam formulation contains arginine,
which can cause airway inflammation after chronic inhalation
therapy in patients with CF (10, 11). The study described herein
included patients with CF who frequently used antibiotics for PA
airway infections and were generally compliant with the recom-
mended standard of care (12). The study assessed the effective-
ness of AZLI in this intensively treated patient population
after pretreatment with tobramycin inhalation solution (TIS),
and compared patient responses to AZLI dosed twice or three
times daily. Early treatment of pulmonary exacerbations has
resulted in fewer hospitalizations; thus, need for hospitalization
has become less clinically relevant as a study endpoint (13–15).
Therefore, clinical deterioration was assessed with a new out-
come measure: time to need for additional antipseudomonal
antibiotics to treat symptoms indicative of pulmonary exacerba-
tion (16). Patient-reported improvements in clinical symptoms
were measured with the Cystic Fibrosis Questionnaire–Revised
(CFQ-R), a validated, health-related, quality-of-life measure
(17–19). An established efficacy measure, change in FEV1, was
also included. This combination of endpoints provided a broad
view of patient responses to AZLI therapy. The results of this
study have been previously published in abstract form (20).
METHODS
Study Design
This randomized, double-blind, placebo-controlled, study was con-
ducted at 56 CF centers in the United States (February 2005–
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September 2006). After screening (Day 242; Figure 1), eligible
patients were enrolled (Day 228), randomly assigned to 75 mg
AZLI (twice or three times daily) or placebo (1:1:1), and began
treatment with open-label TIS (Day 228). At baseline (Day 0),
patients completed the course of TIS and began the randomized
AZLI/placebo treatment. Patients were monitored midtreatment
(Day 14), at end of treatment (Day 28), and during follow-up (Days
42, 56, 70, 84).
A complete physical examination was performed at screening.
Spirometry (American Thoracic Society standards) was performed at
every study visit (before and 30 min after any treatment) (21).
FEV1% predicted values were calculated using the Knudson equa-
tion (22).
TIS (300 mg, twice daily) was administered with the PARI LC
PLUS jet nebulizer and AZLI (75 mg aztreonam, 52.5 mg lysine
monohydrate) or placebo (5 mg lactose), diluted in 1 ml of 0.17%
NaCl (twice or three times daily), with the eFlow (Altera) electronic
nebulizer (PARI Innovative Manufacturers, Midlothian, VA) (23).
Patients self-administered a bronchodilator at home before study
medication and a short-acting b2-agonist 15 minutes before the first
spirometry measurements at study visits. Patients continued any pre-
scribed bronchodilator use, excluding the 6 hours before study visits.
TIS was dispensed on Day 228 and AZLI/placebo on Day 0; used
and unused vials were subsequently collected to assess treatment
compliance. Compliance was defined as missing no more than 1 dose
per day, or receiving >50% doses for TIS (twice daily dosing) and
receiving >66% doses for AZLI/placebo (compliance threshold set for
three-times-daily dosing).
This study was conducted in compliance with the Declaration of
Helsinki. Institutional review boards approved the study for each site
and all patients or their guardians provided written informed consent
before any study procedures.
Study Population
Eligible patients (>6 yr, documented diagnosis of CF) had current PA
airway infections (PA present in expectorated sputum or throat swab
culture at screening), three or more TIS courses within previous year,
the ability to perform reproducible pulmonary function tests, and, at
screening, FEV1 >25% and <75% predicted values and arterial
oxygen saturation >90% on room air. Chronic azithromycin use was
allowed if the regimen was unchanged in the previous 3 months and if
additional antipseudomonal therapy had been used since initiating
azithromycin.
Exclusion criteria included current oral corticosteroid use (equiv-
alent to .10 mg prednisone daily); airway cultures yielding Burkhol-
deria cepacia complex in the previous 2 years; oxygen supplementation,
daily continuous or more than 2 L/minute at night; monobactam-
antibiotic hypersensitivity; inhaled short-acting b2-agonist intolerance;
recent changes in antimicrobial, bronchodilator, antiinflammatory,
corticosteroid medications, or physiotherapy technique/schedule; lung
transplantation; significant acute finding on chest radiograph (e.g.,
lobar infiltrate and atelectasis, pneumothorax, or pleural effusion) at
screening or in previous 90 days; aspartate transaminase (AST) or
alanine transaminase (ALT) more than five times or serum creatinine
more than two times the upper limit of normal (at screening); preg-
Figure 1. Study design and patient disposition.
Patients were randomly assigned to treatment
with aztreonam lysine for inhalation (AZLI)/
placebo before they all began the open-label
tobramycin inhalation solution (TIS) run-in;
their reasons for discontinuing during the TIS
run-in are displayed by randomization group.
The 211 patients remaining in the study at
baseline (Day 0) received at least one dose of
AZLI/placebo and comprise the intent-to-treat
(ITT) population. The category labeled ‘‘Met
primary endpt’’ includes patients who met the
primary efficacy endpoint, need for additional
inhaled, or intravenous antibiotics. * Met pri-
mary endpoint in analyses of Day 84–100 data.
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nancy; lactation; or, in opinion of investigator, medical or psychiatric
illness interfering with study participation.
Efficacy Measures
The primary efficacy endpoint was time to need for additional inhaled
or intravenous antipseudomonal antibiotics to treat symptoms indica-
tive of pulmonary exacerbation. The predefined list of symptoms
included decreased exercise tolerance, increased cough, increased
sputum production/chest congestion, or decreased appetite (16). Major
secondary efficacy endpoints included changes in clinical symptoms
(CFQ-R respiratory symptoms scale), pulmonary function, PA density
(colony-forming units [cfu]/g sputum, log10 transformed), time to
hospitalization, hospitalizations, and weight. Scores for CFQ-R scales
ranged from 0 to 100; increasing scores indicated improvement (19).
The CFQ-R was administered at the beginning of study visits to
minimize any influence of physiologic data or study personnel on
patient responses. The minimal clinically important difference (MCID)
score is the smallest change that a patient can detect on a patient-
reported outcome measure such as the CFQ-R (24, 26). Using re-
sponses during the TIS phase to the respiratory domain of a Global
Rating of Change Questionnaire, an MCID score of 5 was determined
for the CFQ-R respiratory scale (25). Thus, 5-point changes on the
CFQ-R respiratory symptom scale indicated improving or worsening
respiratory symptoms detectable by the patient.
Microbiological endpoints included the minimum inhibitory con-
centration (MIC) of aztreonam for PA, and the prevalence of other
pathogens.
Safety Measures
Safety was assessed by monitoring adverse events and changes in
clinical laboratory values, vital signs, and airway reactivity. Worsening
CF symptoms were treated as adverse events and patients were
withdrawn from the study if they exhibited any of the predefined
symptoms of pulmonary exacerbation (16). Patients who withdrew for
the combination of predefined symptoms and need for additional
inhaled or intravenous antipseudomonal antibiotics met the primary
efficacy endpoint, completing their study participation.
Statistical Analyses
Efficacy and safety analyses included all randomly assigned patients
receiving one or more 1 doses of AZLI/placebo. As specified in the
study protocol, responses of twice-daily placebo and three-times-daily
placebo groups were pooled for the primary efficacy analyses and were
compared with the AZLI-pooled group as a gatekeeper approach. If
the null hypotheses based on pooled data were rejected, then analyses
were conducted on the three-times-daily AZLI and on the twice-daily
AZLI groups (AZLI-TID and AZLI-BID) versus pooled placebo.
Safety analyses were conducted on the pooled placebo, AZLI-BID,
and AZLI-TID groups. All statistical tests were conducted at the two-
sided 0.05 level.
A sample size of 210 patients for AZLI/placebo treatment was
estimated as providing more than 90% power to detect a difference
in time to antibiotic need, with a 5 0.05. The sample size estimate
was based on the Lakatos normal approximation method with
exponential rates of loss to follow-up assumed as 10% for both
treatment groups. Under these distributions, the Day 84 rates were
hypothesized to be 55% placebo (pooled) and 32% AZLI pooled.
Therefore, by the end of Day 84, 39 placebo patients and 45 AZLI
patients were predicted to require additional inhaled or intravenous
antibiotics (the predicted absolute number of events is higher for
AZLI than placebo because there are twice as many patients in the
pooled AZLI group).
CFQ-R and FEV1 efficacy analyses used the last observation
carried forward convention. Analyses of continuous variables used
analysis of covariance models with treatment as the fixed-effect and
baseline (Day 0) values as covariates. The highest aztreonam MIC at
baseline was the covariant for analyzing log10 PA colony-forming units.
Changes in FEV1 (L) and changes in FEV1% predicted were analyzed
using relative values; increases or decreases were calculated as
percentages of the baseline FEV1 or FEV1% predicted values. Time
to antibiotic need and to hospitalization were analyzed using Kaplan-
Meier estimates and treatment groups compared using the log-rank
test. Cox proportional hazards regression was used to estimate hazard
ratios. Hospitalizations were analyzed using Wilcoxon rank sum test
(days) and Fisher’s exact test (proportion of patients). Aztreonam
concentrations (Alta Analytical Laboratory, El Dorado Hills, CA) in
plasma and sputum were summarized, as were aztreonam or tobramy-
cin MIC values inhibiting 50% (MIC50) or 90% (MIC90) of PA isolates,
proportion of patients with aztreonam or tobramycin MIC values
above parenteral breakpoints, and the prevalence of other pathogenic
bacteria (Covance Central Laboratory Services, Indianapolis, IN) (1, 9,
27). SAS versions 8.02 and 9.1 were used (SAS Institute, Inc., Cary,
NC).
If patients needed oral antibiotics without need for additional
inhaled or intravenous antibiotics, they were discontinued from the
study and were not considered as having met the primary endpoint. If
patients needed oral antibiotics and also needed additional inhaled or
intravenous antibiotics, they were discontinued from the study. If they
also had one of the four predefined symptoms indicative of pulmonary
exacerbation, they were considered as having met the primary end-
point. Patients who prematurely discontinued or completed the study
without meeting the criteria for the primary endpoint were to be
censored in the analysis of time to need for inhaled or intravenous
antibiotics due to predefined symptoms. However, some of these
patients were experiencing the precursor of a pulmonary exacerbation.
To minimize any potential bias due to this possibly informative
censoring, patients who were experiencing respiratory symptoms at
the time of early termination or study completion were monitored to
determine if inhaled or intravenous antibiotics were prescribed during
the subsequent 2 weeks. The study protocol specified that patients were
to be followed for safety purposes until adverse events resolved, but
did not specify the inclusion of events after Day 84 in the primary
efficacy endpoint. Analyses of the data collected during this 2-week
period of time were completed before unblinding the study.
RESULTS
Of 363 patients screened, 211 completed the 28-day TIS run-
in and began the 28-day AZLI/placebo treatment; 173 (82%)
completed the AZLI/placebo treatment period, and 90 (43%)
completed the study (Figure 1). Dosing compliance was 99.5%
during TIS run-in and 95.3% during AZLI/placebo treatment.
Patient Characteristics
Patient characteristics appeared generally well balanced be-
tween treatment groups (Table 1). Mean age was 26.2 years;
165 (78%) patients were 18 years or older. The proportion of
patients younger than 18 years in the placebo group (15.8%)
was smaller than that in the AZLI-pooled group (25.2%).
Mean FEV1% predicted was 55.1%; FEV1 was <50% pre-
dicted value for 76 (36%) patients. Concomitant medications
used at screening for more than 50% of patients were pan-
creatic enzymes (92%), salbutamol (89%), dornase alfa (85%),
vitamins (84%), azithromycin (70%), and fluticasone propionate
with salmeterol (56%). Average TIS use was 5.3 courses in the
year before the study; 6.5 courses/year is the maximum number
approved (6).
Patient Disposition during AZLI/Placebo Treatment Period
and Follow-up Period
Of the 121 patients discontinuing the study during the AZLI/
placebo treatment or follow-up periods (Days 0–84), 45 patients
(21% of 211 patients beginning the AZLI/placebo treatment
period) discontinued without meeting the primary study end-
point. The majority of discontinuing patients (76 of 121) met the
primary study endpoint, need for intravenous or inhaled anti-
pseudomonal antibiotics (Days 0–84; AZLI-BID: 17 of 32
withdrawing; AZLI-TID: 21 of 39; placebo: 38 of 50; Figure
1). This group included 11 patients (AZLI-BID: 3 patients;
AZLI-TID: 3 patients; placebo: 5 patients) whose need for
inhaled or intravenous antipseudomonal antibiotics to treat
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symptoms indicative of a pulmonary exacerbation (an event)
occurred after discontinuing from the study. An additional five
patients had an event on the day they completed the study
(AZLI-BID: 2 patients; AZLI-TID: 3 patients); they are
included in the 90 patients listed as completing the study
(Figure 1). Among these 16 patients, 5 had events reported
after study end (Day 84); thus, the time to antibiotic need
analysis was extended beyond study end (Day 84) so that data
from these patients could be included (Figure 2). Of the 81
patients who met the primary endpoint, 17 (21%) received
treatment with intravenous antibiotics (initial treatment or
subsequent to inhaled antibiotics).
Efficacy
The median time to need for additional inhaled or intravenous
antipseudomonal antibiotics to treat symptoms indicative of
pulmonary exacerbation was 21 days longer for the AZLI-
pooled group than for the placebo group (92 vs. 71 d, measured
from baseline; P 5 0.007; Figure 2). Median time to antibiotic
need was also longer in the AZLI-BID (.92 d, P 5 0.002) and
AZLI-TID (87 d, P 5 0.182) groups, compared with placebo
(71 d). This corresponded to a 45% reduction in risk for needing
additional intravenous or inhaled antibiotics. To determine if
these results were overly influenced by including the additional
TABLE 1. PATIENT DEMOGRAPHICS AND CHARACTERISTICS
Placebo AZLI-BID AZLI-TID AZLI-Pooled
(n 5 76) (n 5 69) (n 5 66) (n 5 135)
Age, mean yr (range) 27.9 (10–65) 26.5 (10–50) 24.1 (7–50) 25.3 (7–50)
Age , 18 yr, n (%) 12 (15.8) 17 (24.6) 17 (25.8) 34 (25.2)
Male, n (%) 45 (59.2) 38 (55.1) 38 (57.6) 76 (56.3)
Weight, mean kg (SD) 61.6 (13.0) 57.1 (12.9) 57.7 (16.9) 57.4 (14.9)
BMI, mean kg/m2 (SD) 21.7 (3.0) 20.9 (3.3) 21.0 (4.5) 20.9 (3.9)
TIS courses in previous year, mean 5.26 5.46 5.26 5.36
CFTR genotype, n (%)
Homozygous for DF508 34 (45) 25 (36) 31 (47) 56 (41)
Heterozygous for DF508 20 (26) 15 (22) 12 (18) 27 (20)
Unidentified or other 22 (29) 29 (42) 23 (35) 52 (39)
Dornase alfa use, % patients 89.5 81.2 84.8 83.0
Azithromycin use, % patients 65.8 69.6 74.2 71.9
Hypertonic saline use, % patients 11.8 8.7 12.1 10.4
MIC of tobramycin for all PA isolates, mg/ml
MIC50 2 1 2 1
MIC90 256 16 64 32
No. of isolates tested 137 104 107 211
FEV1% predicted, mean (SD) 53.9 (15.3) 56.3 (14.8) 55.4 (16.3) 55.8 (15.5)
Patients with FEV1 < 50% predicted value, n (%) 30 (39.5) 24 (35.3) 22 (33.3) 46 (34.3)
CFQ-R respiratory score, mean (SD) 62.1 (19.7) 63.1 (16.7) 64.2 (18.1) 63.7 (17.4)
MIC of aztreonam for all PA isolates, mg/ml
MIC50 <1 2 2 2
MIC90 64 64 32 32
Minimum MIC <1 <1 <1 <1
Maximum MIC 1,024 .2,048 1,024 .2,048
No. of isolates tested 125 105 111 216
Definition of abbreviations: AZLI-BID 5 twice-daily dosage of aztreonam lysine for inhalation; AZLI-TID 5 three-times-daily
dosage of aztreonam lysine for inhalation; BMI 5 body mass index; CFQ-R 5 Cystic Fibrosis Questionnaire–Revised; MIC 5
minimum inhibitory concentration; PA 5 Pseudomonas aeruginosa; TIS 5 tobramycin inhalation solution.
Age and concomitant medications were measured at screening; FEV1% predicted and MIC of tobramycin for PA were
measured at Day 228; CFQ-R respiratory scores and MIC of aztreonam for PA were measured at Day 0. There were no statistically
significant differences in demographic or baseline characteristics between the AZLI and placebo groups.
Figure 2. Time to need for additional in-
haled or intravenous antipseudomonal anti-
biotics to treat symptoms indicative of
pulmonary exacerbation. The median time
to antibiotic need is shown for both treat-
ment groups (aztreonam lysine for inhala-
tion [AZLI] vs. placebo, P 5 0.007).
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patient data described above, we also conducted the time to
need analysis using data collected only during the 84-day study
period (Days 0–84). Comparable results were obtained; time to
antibiotic need was significantly longer for AZLI-treated
patients than for placebo-treated patients (P 5 0.002; Figure 2).
We also examined the effects of age. In both age subgroups,
the proportion of patients requiring inhaled or intravenous
antibiotics was smaller in the AZLI-treated group than that in
the placebo-treated group (,18 yr of age: [ALZI pooled: 9 of
34, 26%], [placebo: 5 of 12, 42%]; >18 yr of age: [AZLI pooled:
34 of 101, 34%], [placebo: 33 of 64, 52%]). For patients 18 years
or older, time to need for additional antibiotics was significantly
prolonged for AZLI-treated patients compared with placebo-
treated patients (P 5 0.021). The difference was not significant
for the younger patients; however, the group sizes were small.
Adjusted mean CFQ-R respiratory scores increased 5.01
points in the AZLI-pooled group compared with placebo (Day
28; 95% confidence interval [CI], 0.81–9.21; P 5 0.020).
Significant improvements were observed for both AZLI-BID
and AZLI-TID groups compared with placebo (Figure 3).
Responses of the AZLI-BID and AZLI-TID groups were
comparable. Scores decreased during the follow-up period
(Day 84; AZLI-pooled: 0.71 points; placebo: 20.78 points;
change from Day 0). During AZLI/placebo treatment (Days
0–28), CFQ-R respiratory scores improved for more AZLI-
treated than placebo-treated patients (>5-point increase;
AZLI, 52%; placebo, 37%) and worsened for fewer AZLI-
treated patients (>5-point decrease; AZLI, 28%; placebo, 38%;
overall categorical comparison, P 5 0.029).
Adjusted mean FEV1 improved 6.3% in the AZLI-pooled
group compared with placebo (Day 28; 95% CI, 2.5–10.1; P 5
0.001). Significant improvements were observed for both AZLI-
BID and AZLI-TID groups compared with placebo (Figure 3).
Responses of the AZLI-BID and AZLI-TID groups were
comparable. FEV1 decreased during the follow-up period for
all groups.
All patients received open-label TIS during the run-in period
(Days 228 to 0). By chance, only the group that later received
AZLI-TID had a notable improvement in observed FEV1
(Figure E1 of the online supplement).
Adjusted mean relative FEV1% predicted also improved in
the AZLI-pooled group compared with placebo (Day 28;
adjusted means; AZLI-pooled, 4.1%; placebo, 22.5%; treat-
ment effect 5 6.6%; 95% CI, 2.8–10.4; P , 0.001).
Changes in CFQ-R respiratory scores at end of treatment
(Day 28) were modestly correlated with changes in FEV1
(Pearson correlation coefficients 5 0.33, 0.24, 0.33, for AZLI-
BID, AZLI-TID, placebo groups, respectively; Figure E2) and
with Global Rating of Change Questionnaire respiratory do-
main responses (Pearson correlation coefficient 5 0.46; all
groups combined, P , 0.001).
Adjusted mean PA sputum density decreased 0.66 log10 PA
cfu/g sputum in the AZLI-pooled group compared with the
placebo group (Day 28: 95% CI. 21.13 to 20.19; P 5 0.006).
Significant decreases were observed for both AZLI-BID and
AZLI-TID compared with placebo groups (Figure 3). At Day
14, responses of the AZLI-TID group were larger than those of
the AZLI-BID group and, by Day 28, the responses of the
AZLI-BID and AZLI-TID groups were comparable. PA den-
sity increased for all groups during the follow-up period.
During the 28-day TIS run-in, mean (SE) CFQ-R respiratory
scores decreased 21.47 (0.98), mean FEV1 increased 0.9%
(0.8%), and mean PA density decreased 0.28 (0.14) log10 PA
cfu/g sputum.
Time to first hospitalization and median days per number
of patients hospitalized did not differ significantly between
treatment groups (Days 0–84). Weight increased 0.77% for
the AZLI-pooled group compared with placebo (Day 28: 95%
CI, 0.00–1.55; P 5 0.051).
Safety
The incidence of treatment-emergent adverse events was gen-
erally comparable for the three groups (Table 2); any differ-
ences were not statistically significant. Nine patients were
hospitalized because of serious adverse events occurring during
the AZLI/placebo treatment period: seven for pulmonary
exacerbation (AZLI-BID: 2; AZLI-TID: 4; placebo: 1) and
one each for small bowel obstruction (AZLI-BID) and hypo-
natremia (AZLI-TID). There were no deaths during this study
and no reports of anaphylaxis. Airway reactivity after treatment
(acute FEV1 decrease >15% within 30 min post-treatment;
Days 0, 14) occurred in six patients (AZLI-pooled, 4 [3.0%];
placebo, 2 [2.6%]); none of these patients withdrew for this
reason.
Mean changes in vital signs and in hematology and serum
chemistry variables from Day 228 or Day 0 were comparable
for all treatment groups during the study. Mean total white
blood cell counts, neutrophil counts, % neutrophils, and serum
glucose concentrations were near or above the upper limit of
normal for all treatment groups throughout the study.
Figure 3. Changes in Mean Cystic Fibrosis Questionnaire–Revised
(CFQ-R) respiratory scores, FEV1, and Pseudomonas aeruginosa (PA)
density in sputum. Child, teen, and adult CFQ-R respiratory scores were
combined. The CFQ-R was not administered on Day 42. For CFQ-R
respiratory, at Day 28, P 5 0.021 for AZLI-BID versus placebo and P 5
0.092 for AZLI-TID versus placebo. For FEV1 at Day 28, P 5 0.006 for
AZLI-BID versus placebo and P 5 0.005 for AZLI-TID versus placebo. For
PA density (log10 PA cfu/g sputum) at Day 28, P 5 0.011 for AZLI-BID
versus placebo and P 5 0.031 for AZLI-TID versus placebo. BID 5 twice
daily; TID 5 three times daily.
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Clinical Pharmacology and Microbiology
Aztreonam concentrations in plasma 1 hour after dosing were
as follows (median [range]): AZLI-BID, 533 (0–1,390) ng/ml,
and AZLI-TID, 585 (0–2,920) ng/ml on Day 0 (n 5 66, 63); and
AZLI-BID, 581 (45–1,540) ng/ml, and AZLI-TID, 622 (31–
1,710) ng/ml on Day 14 (n 5 65, 59). Aztreonam concentrations
in sputum 10 minutes after dosing were as follows: AZLI-BID,
422 (0–2,160) mg/g, and AZLI-TID, 537 (0.2–3,010) mg/g on Day
0 (n 5 63, 58); and AZLI-BID, 429 (0.3–3,430) mg/g, and AZLI-
TID, 406 (68–3,240) mg/g on Day 14 (n 5 61, 51).
MIC50 and MIC90 values of aztreonam for PA remained
unchanged between Days 0 and 56 except for a transient four-
fold increase on Day 14 in the AZLI-TID group (Table 3). The
proportion of patients who had PA isolates with aztreonam
MIC values greater than 8 mg/ml (parenteral breakpoint) in-
creased during AZLI treatment; the increase was transient in
the AZLI-TID group (Day 0, 28, 42: AZLI-BID: 27%, 44%,
39%; AZLI-TID: 33%, 43%, 28%; placebo: 38%, 37%, 30%,
respectively) (1). MIC50 and MIC90 values of tobramycin for PA
isolates changed less than fourfold (Days 228 to 56). The
proportion of patients who had PA with tobramycin MIC values
of 8 mg/ml or more (parenteral breakpoint) did not increase
(Days 228 to 42). No persistent increases were observed for the
prevalence of Staphylococcus aureus, Stenotrophomonas malto-
philia, or Achromobacter xylosoxidans (Days 0–28); B. cepacia
complex was not isolated.
DISCUSSION
AZLI at a dose of 75 mg, twice or three times daily for 28 days
significantly delayed time to need for additional inhaled or
intravenous antipseudomonal antibiotics to treat respiratory
symptoms indicative of pulmonary exacerbation in patients
with CF. Compared with placebo, AZLI treatment also signif-
icantly improved respiratory symptoms and pulmonary function
and significantly decreased log10 PA colony-forming units.
AZLI was well tolerated; adverse events were generally con-
sistent with the symptoms of CF lung disease.
In general, responses to twice- and three-times-daily AZLI
were comparable. The reduction in PA density appeared sooner
for the AZLI-TID than for the AZLI-BID group and time to
antibiotic need was somewhat longer for the AZLI-BID than for
the AZLI-TID group. The larger increase observed for the
AZLI-TID group than for the other groups during the TIS
pretreatment period likely occurred by chance, because all three
groups were receiving open-label TIS. For the AZLI-TID group,
the additive improvement in lung function responses resulting
from back to back treatment with TIS and three-times-daily
AZLI approached 10%. Upon withdrawal of therapy, the sub-
sequent rapid decrease in lung function may have been apparent
to both patients and investigators, and may have contributed to
the shorter time to antibiotic need observed for the AZLI-TID
group than for the AZLI-BID group. These results suggest that
a time-to-need study design may be more applicable for a contin-
uous rather than an episodic therapeutic intervention if the
intervention leads to short-term improvements that decrease
rapidly after therapy is withdrawn. Overall, the two AZLI dosing
regimens in this study appeared to be generally comparable; no
AZLI dose–response was observed. It will be interesting to see if
similar results are obtained from the ongoing open-label, multi-
cycle AZLI study of twice- and three-times-daily dosing.
The increased CFQ-R respiratory scores indicated that
patients perceived their respiratory symptoms as improving
after AZLI treatment. CFQ-R respiratory scores appeared to
detect change in this CF population with sensitivity equal to
FEV1, the established efficacy endpoint. However, these end-
points are measuring different aspects of clinical efficacy, as
indicated by the modest correlation between patient-reported
changes in respiratory symptoms (CFQ-R respiratory) and
measured changes in lung function (FEV1) (28).
The decrease in PA sputum density after AZLI treatment was
small but statistically significant and was observed in clinically
stable patients immediately after a course of TIS. The decrease
was comparable to those observed in previous TIS studies en-
rolling intensively treated patients, but smaller than those ob-
served in a previous AZLI study enrolling less intensively treated
patients (29–31). Thus, for PA density, the magnitude of change
appears to be dependent on recent antibiotic therapies. There was
no evidence for development of microbial resistance to aztreo-
nam during this study, but this will need to be examined over
longer time periods and multiple treatment courses.
TABLE 2. TREATMENT-EMERGENT ADVERSE EVENTS OF 5.0% OR MORE IN ANY TREATMENT GROUP
DURING THE AZLI/PLACEBO TREATMENT PERIOD
TEAEs >5% in any Treatment Placebo AZLI-BID AZLI-TID AZLI-Pooled
Group* (n 5 76) (n 5 69) (n 5 66) (n 5 135)
Cough, n (%) 26 (34.2) 19 (27.5) 24 (36.4) 43 (31.9)
Productive cough, n (%) 13 (17.1) 9 (13.0) 9 (13.6) 18 (13.3)
Wheezing, n (%) 6 (7.9) 5 (7.2) 9 (13.6) 14 (10.4)
Hemoptysis, n (%) 7 (9.2) 7 (10.1) 6 (9.1) 13 (9.6)
Nasal congestion, n (%) 6 (7.9) 5 (7.2) 5 (7.6) 10 (7.4)
Rhinorrhea, n (%) 2 (2.6) 5 (7.2) 5 (7.6) 10 (7.4)
Headache, n (%) 5 (6.6) 2 (2.9) 6 (9.1) 8 (5.9)
Pharyngolaryngeal pain, n (%) 7 (9.2) 3 (4.3) 5 (7.6) 8 (5.9)
Dyspnea, n (%) 3 (3.9) 2 (2.9) 5 (7.6) 7 (5.2)
Pyrexia, n (%) 2 (2.6) 4 (5.8) 3 (4.5) 7 (5.2)
Respiratory tract congestion, n (%) 5 (6.6) 5 (7.2) 2 (3.0) 7 (5.2)
Abdominal pain, upper, n (%) 3 (3.9) 4 (5.8) 1 (1.5) 5 (3.7)
Decreased appetite, n (%) 5 (6.6) 4 (5.8) 1 (1.5) 5 (3.7)
Fatigue, n (%) 7 (9.2) 3 (4.3) 2 (3.0) 5 (3.7)
Dysphonia, n (%) 4 (5.3) 1 (1.4) 1 (1.5) 2 (1.5)
Exercise tolerance decreased, n (%) 4 (5.3) 1 (1.4) 1 (1.5) 2 (1.5)
Sinus congestion, n (%) 5 (5.6) 0 (0.0) 2 (3.0) 2 (1.5)
Definition of abbreviations: AZLI-BID 5 twice-daily dosage of aztreonam lysine for inhalation; AZLI-TID 5 three-times-daily
dosage of aztreonam lysine for inhalation; TEAE 5 treatment-emergent adverse events.
* TEAEs coded using the Medical Dictionary for Regulatory Activities (MedDRA) preferred term; for TEAEs with incidence >10%
in any group, % patients for each TEAE did not differ significantly between treatment groups (Fisher’s exact test).
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Patients in this study were predominantly adults (78% >18 yr)
and were largely compliant with the current guidelines of care for
patients with CF (12). In addition to the TIS run-in, TIS use in the
previous year averaged 5.3 courses, approaching the maximum of
6.5 courses approved per year (6). Thus, the magnitude of
improvement in FEV1 (6.3%) and FEV1% predicted (6.6%)
after AZLI treatment was unexpected, and suggests that lung
disease in adults with CF may be more responsive to additional
treatment than previously believed. The large proportion of
adults enrolled also likely reflects the changing demographics of
patients with CF; as the standard of care improves, there are
fewer patients younger than 18 years with moderate to severe
lung disease and chronic PA airway infection (1, 2, 5–8).
Although the study entry criteria were comparable, patients
in this study were older (26 vs. 21 yr) with higher mean FEV1%
predicted (55 vs. 50–51%) than patients in TIS studies a decade
ago (5). This patient population, despite being older, had less
lung disease progression; this also likely reflects the improved
clinical management of CF (1, 2, 5–8).
Patient responses during the TIS run-in period appeared
markedly attenuated compared with responses observed in
previous TIS studies (5, 13, 14, 29, 32, 33). Further studies will
be required to elucidate the mechanism(s) underlying this
apparent attenuation in clinical efficacy resulting from chronic
TIS use. An increase in FEV1 was observed after 28 days of
AZLI treatment; therefore, AZLI appears to circumvent the
mechanism(s) affecting patient responses to TIS. However, this
study included only one treatment period and the effectiveness
of AZLI needs to be examined over longer time periods and
multiple treatment courses.
The results of this study indicate that AZLI may be an
effective add-on therapy for patients with CF and chronic PA
airway infection who are intensively treated with TIS; in 2005,
this group included 58% of patients in the United States (.5 yr
of age) with CF and PA airway infection (2). The improvements
in FEV1 and PA sputum density decreased during the 2 weeks
after therapy stopped. Thus, to maintain lung function, future
strategies for managing patients may include rotating use of
different inhaled antibiotics or use of combination therapies.
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